If this is the case, then inhibition of the SAA/NFAT5 axis, for example, via shRNA or small molecule intervention, would repress the interorgan communication and represent therapeutic strategies for chronic inflammatory diseases characterized by excessive production of SAA, including encephalomyelitis, inflammatory bowel disease, and RA (48, 49). The gene discussed is NFAT5; the disease is rheumatoid arthritis.